EX-32 8 cldx-20231231xex32.htm EX-32

Exhibit 32

​

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Celldex Therapeutics, Inc. (the “Company”), that, to his knowledge, the Annual Report of the Company on Form 10-K for the period ended December 31, 2023 (the “Form 10-K”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Form 10-K. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

​

Date: February 26, 2024 |  | By: | /s/ ANTHONY S. MARUCCI
​ | ​ | ​ | Name: Anthony S. Marucci
​ | ​ | ​ | Title: President and Chief Executive Officer
​ | ​ | ​ | ​
Date: February 26, 2024 | ​ | By: | /s/ SAM MARTIN
​ | ​ | ​ | Name: Sam Martin
​ | ​ | ​ | Title: Senior Vice President and Chief Financial Officer

​

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.